|
More
Research Services
Research Library
|
|
SGS Life Science Services - Clinical Research
|
Outsourcing is one of the commonly used approaches by pharmaceutical companies. Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit growth. There are a number of trends and forces within the pharmaceutical industry that are causing companies to rethink their approaches to growth and cost management.
|
|
|
SGS Life Science Services - Clinical Research
|
Drug administration is a common cause of torsades de pointes (TdP). Among these drugs are the QT-prolonging antiarrhythmics (e.g. quinidine, sotalol, dofetilide, ibutilide) and a wide range of drugs developed for non-cardiovascular indications (e.g. erythromycin, fluoroquinolones, thioridazine) and other antipsychotics. An up-to-date list of drugs inducing TdP is available on the Internet. The ...
|
|
|
SGS Life Science Services - Clinical Research
|
The European Commission announced its intention to introduce the most significant re-design of the EU's Pharmacovigilance (PV) system in the last 40 years. Following a recent public consultation, the Commission aims to significantly strengthen and rationalize the system, in order to make it appropriate for an enlarged EU with innovative products, modern information technology and study designs.
|
|
|
SGS Life Science Services - Clinical Research
|
Over the past number of years HIV medication development mainly focused on treatment simplification with the development of fixed dose combination tablets. However, during the last two years, significant progress was made to increase the number of new compounds available to patients; not only did the FDA approve a new protease inhibitor (duranavir, 2006) and a NNRTI (Etravirine, 2008), there was ...
|
|
|
Quintiles
|
In its response to the cacophony of demands for cost-effective, innovative medicines, the biopharmaceutical industry has a unique chance to influence the U.S. health care landscape. The traditional model of pharmaceutical R&D in which a steady stream of broadly indicated blockbusters gave market-based rewards is a rapidly fading memory. While products are becoming more targeted to smaller patient ...
|
|
|
|
